Zynex, Inc. (ZYXI) Tops Q4 EPS by 1c, Revenues Beat; Offers 1Q Revenue Guidance Above Consensus

Zynex, Inc. (NASDAQ: ZYXI) reported Q4 EPS of $0.08, $0.01 better than the analyst estimate of $0.07. Revenue for the quarter came in at $9.3 million versus the consensus estimate of $8.82 million.

Thomas Sandgaard, CEO said: "We finished 2018 strong with revenue of $9.3 million in the fourth quarter and net income of $2.6 million. Orders grew 35% compared to the fourth quarter of 2017 and were 12% higher than the third quarter of 2018. Orders grew 33% for the full year 2018. Our gross profit margin was 80% for the quarter and 81% for the full year.

We continue to invest in expanding our sales force and have recently increased the pace of adding new sales reps. We expect the addition of new sales reps to have an impact in order and revenue growth this year and going forward.

We continue to advocate for pain patients, and for physicians to prescribe our NexWave technology as the first line of defense in treating chronic and acute pain without side effects. We are dedicated to promoting our technology in an effort to remove patient addiction and other side effects from prescription opioids."

GUIDANCE:

Zynex, Inc. sees Q1 2019 revenue of $8.3-8.8 million, versus the consensus of $8.07 million.

For earnings history and earnings-related data on Zynex, Inc. (ZYXI) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Eldorado Gold elects nine directors at 2026 annual meeting
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance